ArticleGynecologic oncology reports2025
Increased proportion of "other hrHPV" genotypes other than 16 and 18/45 among women attending ART clinic in Northern Uganda.
Article in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Introduction: Cervical cancer, caused by persistent infection with High-Risk Human Papillomavirus (hrHPV) disproportionately affects women living with HIV Methods: From August to October of 2024, a cross-sectional descriptive analytical study was carried out at GRRH. We enrolled 346 women living with HIV through convenient sampling. Cervical swab specimens were collected and analyzed for hrHPV genotypes using the CEPHIED GeneXpert HPV assay Model type GX XVI 16 serial number 846215. STATA version 14 was used to analyze quantitative data, and associations were tested using logistic regression considering p values of <0.05 as statistically significant. Findings: Overall, 29.5 % (95 % CI: 24-34 %) of participants had hrHPV. The most prevalent category of HPV genotype was "Other hrHPV" (31, 33, 35, 39, 51, 52, 56, 58, 59, 66, and 68) (75.2 %) while HPV 18/45 and HPV 16 had prevalence of 15.7 % and 9.1 % respectively. Being professionally employed was significantly associated with reduced odds of hrHPV infection (aOR = 0.293, Conclusion: Women on ART at Gulu RRH, Gulu district, had an elevated prevalence of hrHPV especially those HPV genotypes categorized as "Other hrHPV". Unemployment was associated with increased odds of hrHPV among the study participants. This calls for extended HPV genotyping during screening and customization of HPV vaccination to cover all HPV genotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.